| It is a bone resorption inhibitor. |
|Composition : ||15mg, 30mg, 60mg, 90mg|
|Indications :||Hypercalcaemia of malignancy, Paget's disease, Osteolytic bone metastasis of breast cancer, and Osteolytic lesions of multiple myeloma.|
|Contraindications :||Patients with clinically significant hypersensitivity to pamidronate or other biphosphonates.|
|Safety Profile :||Standard hypercalcemia related metabolic parameters such as serum levels of calcium, phosphate, magnesium and potassium should be carefully monitored.|
|Adverse Effects :||Fluid overload, generalized pain, Hypertension, abdominal pain, anorexia, constipation, nausea, vomiting, urinary tract infection, bone pain, anaemia, hypophosphatemia.|
|Dosage :||Paget's disease - 60mg by slow iv infusion at a rate of 15mg/hour, optimal dosing regimen adjusted individually according to response.|
Hypercalcaemia of malignancy : Slow iv infusion at a rate of 60 mg/hour dose adjusted according to initial plasma calcium concentration : 30mg when plasma calcium is below 3.00 mmol/L, 30-60mg when plasma calcium 3.0-3.5 mmol/L, 60-90 mg when plasma calcium 3.5-40 mmol/L, 90 mg when plasma calcium is above 4.0 mmol/L Repeat dose every 2-3 weeks as necessary.
Bone metastasIs : Slow iv infusion 2 hours in breast cancer, 4 hours in multiple myeloma, 90mg every 3-4 weeks.
|Purity :||Not less than 99%.|| |